A Phase II Trial of Anlotinib plus EGFR-TKIs in Advanced Non-Small Cell Lung Cancer with Gradual, Oligo, or Potential Progression After EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)

Anlotinib in combination with continuation of EGFR-tyrosine kinase inhibitors (TKIs) prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression.